Approval · Notice of Compliance 33177 · 2024
EVISTA: Notice of Compliance 33177
Issued May 2, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33177
- Date
- May 2, 2024
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of two drug substance manufacturing sites
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EVISTA | Not yet assigned | — |
Medicinal ingredients
- RALOXIFENE HCL 60 MG per TAB